These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8387762

  • 1. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
    Takigawa N, Ohnoshi T, Ueoka H, Yonei T, Kiura K, Tabata M, Kodani T, Kamei H, Segawa Y, Shibayama T.
    Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
    [Abstract] [Full Text] [Related]

  • 2. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
    Kiura K, Ohnoshi T, Ueoka H, Takigawa N, Tabata M, Segawa Y, Shibayama T, Kimura I.
    Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
    [Abstract] [Full Text] [Related]

  • 3. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R.
    Oncol Res; 1996 Dec; 8(6):229-38. PubMed ID: 8895198
    [Abstract] [Full Text] [Related]

  • 4. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S, Zijlstra JG, de Vries EG, Mulder NH.
    Cancer Res; 1990 Jan 15; 50(2):304-9. PubMed ID: 1967222
    [Abstract] [Full Text] [Related]

  • 5. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line.
    Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I.
    Acta Med Okayama; 1992 Jun 15; 46(3):203-12. PubMed ID: 1354408
    [Abstract] [Full Text] [Related]

  • 6. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
    Kimura I, Ohnoshi T, Hiraki S, Miyamoto H.
    Gan To Kagaku Ryoho; 1987 Mar 15; 14(3 Pt 2):830-6. PubMed ID: 3032107
    [Abstract] [Full Text] [Related]

  • 7. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S, Kooistra AJ, de Vries EG, Mulder NH, Zijlstra JG.
    Cancer Res; 1993 Mar 01; 53(5):1064-71. PubMed ID: 8382551
    [Abstract] [Full Text] [Related]

  • 8. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K, Nakamura T, Ono M, Kusano T, Okada K, Kikuchi A, Adachi N, Kohno K, Higashi K, Kuwano M.
    Oncol Res; 1996 Mar 01; 8(5):197-206. PubMed ID: 8884812
    [Abstract] [Full Text] [Related]

  • 9. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH.
    Cancer Res; 1995 Apr 15; 55(8):1707-16. PubMed ID: 7712479
    [Abstract] [Full Text] [Related]

  • 10. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP.
    Cancer Res; 1993 Oct 15; 53(20):4866-73. PubMed ID: 8104687
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
    Parajuli P, Yano S, Nishioka Y, Nokihara H, Hanibuchi M, Nishimura N, Utsugi T, Sone S.
    Oncol Res; 1999 Oct 15; 11(5):219-24. PubMed ID: 10608616
    [Abstract] [Full Text] [Related]

  • 12. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Oct 15; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

  • 13. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
    Withoff S, Smit EF, Meersma GJ, van den Berg A, Timmer-Bosscha H, Kok K, Postmus PE, Mulder NH, de Vries EG, Buys CH.
    Lab Invest; 1994 Jul 15; 71(1):61-6. PubMed ID: 8041119
    [Abstract] [Full Text] [Related]

  • 14. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW, Mirski SE, Cole SP, Sullivan DM.
    Cancer Res; 1994 Feb 01; 54(3):756-62. PubMed ID: 8306338
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T, Harada M.
    Anticancer Res; 1998 Feb 01; 18(2A):927-33. PubMed ID: 9615743
    [Abstract] [Full Text] [Related]

  • 16. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q, Mirski SE, Sparks KE, Cole SP.
    Biochemistry; 1997 May 13; 36(19):5868-77. PubMed ID: 9153428
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
    McPherson JP, Brown GA, Goldenberg GJ.
    Cancer Res; 1993 Dec 15; 53(24):5885-9. PubMed ID: 8261398
    [Abstract] [Full Text] [Related]

  • 18. A novel use for the comet assay: detection of topoisomerase II inhibitors.
    Salti GI, Das Gupta TK, Constantinou AI.
    Anticancer Res; 2000 Dec 15; 20(5A):3189-93. PubMed ID: 11062742
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 20. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
    Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ.
    Cancer Res; 1995 Jan 01; 55(1):78-82. PubMed ID: 7805045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.